Short- and long-term mortality in patients with urosepsis caused by Escherichia coli susceptible and resistant to 3rd generation cephalosporins - BMC Infectious Diseases - BMC Infectious Diseases
Hoban DJ, Nicolle LE, Badal R, et al. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009–2010. Diagn Microbiol Infect Dis. 2011;70:507–11.
Huang YWY, Alleyne A, Leung V, et al. Urosepsis due to extended-spectrum β-lactamase-producing Escherichia coli: a retrospective, single-centre review of risk factors and clinical outcomes. Can J Hosp Pharm. 2018;71:119–27.
Hawser SP, Badal RE, Bouchillon SK, et al. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. Int J Antimicrob Agents. 2010;36:293–4.
M100-S25: Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
Huang Y, Carroll KC, Cosgrove SE, et al. Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing. J Clin Microbiol. 2014;52:2228–30.
Bhalodi AA, Magnano P 3rd, Humphries RM. Performance of ceftriaxone susceptibility testing on the Accelerate Pheno® system of ESBL-producing isolates. Diagn Microbiol Infect Dis. 2020;98(4): 115171.
Kohner PC, Robberts FJ, Cockerill FR 3rd, Patel R. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol. 2009;47(8):2419–25.
Rodríguez-Baño J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;43:1407–14.
Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–20.
Saltoglu N, Karali R, Yemisen M, et al. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities. Int J Clin Pract. 2015;69:766–70.
Yamamichi F, Shigemura K, Kitagawa K, et al. Shock due to urosepsis: a multicentre study. Can Urol Assoc J. 2017;11:E105–9.
Wagenlehner FME, Pilatz A, Weidner W, et al. Urosepsis: overview of the diagnostic and treatment challenges. Microbiol Spectr. 2015;3.
Wagenlehner FM, Lichtenstern C, Rolfes C, Mayer K, Uhle F, Weidner W, Weigand MA. Diagnosis and management for urosepsis. Int J Urol. 2013;20(10):963–70.
Radovanovic D, Seifert B, Urban P, et al. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart. 2014;100:288–94.
Al-Hasan MN, Lahr BD, Eckel-Passow JE, et al. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clin Microbiol Infect. 2013;19:948–54.
Goyal D, Dean N, Neill S, et al. Risk factors for community-acquired extended-spectrum beta-lactamase-producing enterobacteriaceae infections—a retrospective study of symptomatic urinary tract infections. Open Forum Infect Dis. 2019;6:ofy357.
Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55:3485–90.
Augustine MR, Testerman TL, Justo JA, et al. Clinical risk score for prediction of extended-spectrum β-lactamase-producing enterobacteriaceae in bloodstream isolates. Infect Control Hosp Epidemiol. 2017;38:266–72.
Goodman KE, Lessler J, Cosgrove SE, et al. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum β-lactamase-producing organism. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63:896–903.
Chopra T, Marchaim D, Johnson PC, et al. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumoniae: a focus on antimicrobials including cefepime. Am J Infect Control. 2015;43:719–23.
Al-Badr A, Al-Shaikh G. Recurrent urinary tract infections management in women. Sultan Qaboos Univ Med J. 2013;13(3):359–67.
Skippen I, Shemko M, Turton J, et al. Epidemiology of infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp: a nested case–control study from a tertiary hospital in London. J Hosp Infect. 2006;64:115–23.
Leistner R, Bloch A, Gastmeier P, et al. E. coli bacteremia in comparison to K. pneumoniae bacteremia: influence of pathogen species and ESBL production on 7-day mortality. Antimicrob Resist Infect Control. 2016;5:37.
Rottier WC, Ammerlaan HSM, Bonten MJM. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67:1311–20.
Ryan J, McLornan L, O'Neill E. The impact of increasing antimicrobial resistance in the treatment of urosepsis. Ir J Med Sci. 1971;2019(189):611–5.
Richelsen R, Smit J, Schønheyder HC, Laxsen Anru P, Gutiérrez-Gutiérrez B, Rodríguez-Bãno J, Nielsen H. Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark. J Antimicrob Chemother. 2020;75(12):3656–64.
de Lastours V, Laouénan C, Royer G, Carbonnelle E, Lepeule R, Esposito-Farèse M, Clermont O, Duval X, Fantin B, Mentré F, Decousser JW, Denamur E, Lefort A. Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it. J Antimicrob Chemother. 2020;75(8):2334–43.
Mark DG, Hung YY, Salim Z, Tarlton NJ, Torres E, Frazee BW. Third-generation cephalosporin resistance and associated discordant antibiotic treatment in emergency department febrile urinary tract infections. Ann Emerg Med. 2021;78(3):357–69.
Lee CC, Lee CH, Hong MY, Hsieh CC, Tang HJ, Ko WC. Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia. J Microbiol Immunol Infect. 2018;51(4):519–26.
Zohar I, Schwartz O, Yossepowitch O, et al. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2020;75:458–65.
Elbaz M, Zadka H, Weiss-Meilik A, Ben-Ami R. Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. J Antimicrob Chemother. 2020;75(8):2307–13.
Ardá V, Trick WE, Zhang H, Schwartz DN. Spatial, ecologic, and clinical epidemiology of community-onset, ceftriaxone-resistant enterobacteriaceae, cook county, Illinois, USA. Emerg Infect Dis. 2021;27(8):2127–34.
Tamma PD, Smith TT, Adebayo A, Karaba SM, Jacobs E, Wakefield T, Nguyen K, Whitfield NN, Simner PJ. Prevalence of blaCTX-M Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States. J Clin Microbiol. 2021;59(6):e00127-e221.
Comments
Post a Comment